Basiliximab Intravenous and Endodan

• Generic Name: basiliximab
• Dosage Forms: n.a.
• Other Brand Names: Simulect

Basiliximab belongs to a group of medicines known as immunosuppressive agents. It is used to lower the body's natural immunity in patients who receive kidney transplants.

When a patient receives a kidney transplant, the body's white blood cells will try to get rid of (reject) the transplanted kidney. Basiliximab works by preventing the white blood cells from getting rid of the transplanted kidney. The effect of basiliximab on the white blood cells may also reduce the body's ability to fight infections.

Basiliximab is to be administered only by or under the immediate supervision of your doctor.

• Generic Name: aspirin / oxycodone
• Dosage Forms: tablet
• Other Brand Names: Percodan, Percodan-Demi, Roxiprin, Endodan

Oxycodone and aspirin combination is used to relieve pain severe enough to require opioid treatment and when other pain medicines did not work well enough or cannot be tolerated. Oxycodone belongs to the group of medicines called narcotic analgesics (pain medicines). It acts on the central nervous system (CNS) to relieve pain.

Aspirin is used to relieve pain and reduce fever in patients. Aspirin belongs to the group of medicines known as salicylates and acts on the immune system to reduce inflammation. It is also known as an antiinflammatory analgesic.

When oxycodone is used for a long time, it may become habit-forming, causing mental or physical dependence. However, people who have continuing pain should not let the fear of dependence keep them from using narcotics to relieve their pain. Mental dependence (addiction) is not likely to occur when narcotics are used for this purpose. Physical dependence may lead to withdrawal side effects if treatment is stopped suddenly. However, severe withdrawal side effects can usually be prevented by gradually reducing the dose over a period of time before treatment is stopped completely.

This medicine is available only under a restricted distribution program called the Opioid Analgesic REMS (Risk Evaluation and Mitigation Strategy) program.